Compare Nebius Group NV (NBIS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Zimmer Biomet Holdings Inc — how do they compare? Nebius Group NV trades at $251.16 (market cap $49.06B), while Zimmer Biomet Holdings Inc trades at $97.01 (market cap $18.55B). The key difference: Nebius Group NV is far larger — about 2.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | ZBH | |
|---|---|---|
Market Cap | $49.06B | $18.55B |
Sector | Technology | Health |
52-Week High | $286.69 | $107.71 |
52-Week Low | $64.06 | $79.58 |
Enterprise Value | $49.26B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS stock trades at $249.82, up 35.69% in 24 hours, driven by strong Q2 2026 earnings beats and positive AI cloud demand sentiment. Technicals are bearish with key support at $190 and resistance at $196, while fundamentals show rapid revenue growth but negative EPS and high valuation multiples. Recent news highlights Michael Burry's short position alongside upbeat analyst coverage.
Outlook is mixed: high growth in AI infrastructure offers upside, but execution risks, negative earnings, and stretched valuations pose significant challenges. Analyst consensus is bullish with an $248.73 price target, yet competitive pressures and capital intensity require careful monitoring for sustained shareholder value.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
